(1170) Evaluation of Comprehensive Medication Review Quality Performed by Community Pharmacists

Objectives: The purpose of this study is to evaluate the quality of comprehensive medication reviews (CMRs) performed in community pharmacies to demonstrate pharmacists can address standard THERAPY gaps to improve health outcomes. Medication therapy management (MTM) is a unique set of services that allow pharmacists to dedicate individual time with patients to provide clinically impactful experiences. A CMR is a highly regarded, reimbursable service a pharmacist may perform under the umbrella term of MTM services. Medicare Part D sponsors are required to offer an annual CMR, along with quarterly targeted-medication reviews (TMRs) to their eligible beneficiaries. CMRs are intended to improve patient’s knowledge of their medications and to empower self-management of medications and health conditions. CMRs may be delivered face-to-face, telephonically, or through telehealth services with either the patient or patient’s representative. When a pharmacist identifies drug therapy problems (DTPs) during a CMR, they may intervene and collaborate with other health care professionals to optimize patients’ THERAPY. Numerous studies support community pharmacist’s ability to close THERAPY gaps through various MTM integration methods. Further studies are needed to evaluate and prove the quality OF CMR OUTCOMES AND ACCEPTANCE OF RECOMMENDATIONS MADE BY community pharmacists. The primary objective of this study is to evaluate the quality of CMRs performed by assessing the percent with DTPs identified AND NUMBER OF THERAPY GAPS RESOLVED. The secondary objectives are to assess CMR quality based on mode of delivery and to evaluate if trends exist between Social Vulnerability Index (SVI) score and DTPs identified.

Methods: This study will retrospectively evaluate the quality of CMRs performed by pharmacists in a large community pharmacy chain between January 2021 to December 2023. The large community pharmacy chain operates over 2,200 pharmacies across 35 states. INVESTIGATORS WILL EVALUATE APPROXIMATELY 50,000 CMRS WITHIN THE STUDY TIME FRAME. THIS STUDY IS APPROVED THROUGH THE University of Cincinnati’s Institutional Review Board.

Pharmacists in the organization utilize an existing MTM platform that identifies and targets patients for CMRs based on Centers for Medicare and Medicaid Services eligibility criteria. Patient-specific information from the MTM platform will be cross-referenced with the pharmacy management system to EVALUATE THE STUDY OBJECTIVES. The primary objective is TO DETERMINE THE PERCENT OF CMRS WITH DTPS IDENTIFIED. WHEN THE PHARMACIST DOCUMENTS A CMR WITHIN THE EXISTING MTM PLATFORM, THEY MAY ELECT TO ADD A THERAPY GAP TO THE PATIENT’S TAKE-AWAY. WHEN ADDING A THERAPY GAP, THE SYSTEM AUTOMATICALLY CATEGORIZES THE CMR AS “DTPS IDENTIFIED”. IF THE PHARMACIST DOES NOT DOCUMENT A THERAPY GAP, THE SYSTEM CATEGORIZES THE CMR AS “NO DTPS IDENTIFIED”. BOTH CMR TYPES WILL BE EVALUATED FOR ALL RESOLVED THERAPY GAPS. ALL CMRS WILL BE EVALUATED FOR addressed therapy gaps six months post CMR completion using descriptive statistics and trend analysis. THIS STUDY WILL INCLUDE THERAPY GAPS SUCH AS VACCINATION ADMINISTRATIONS, MEDICATION ADHERENCE INTERVENTION COMPLETION, REFILL PROGRAM ENROLLMENT, AND TMRS COMPLETED IN THE EXISITING MTM PLATFORM. A QUALITY CHECK WILL BE PERFORMED WITH 5-15% OF CMRS BY COMPARING THE NUMBER OF THERAPY GAPS RESOLVED PER CMR TO THE TYPE OF CMR DOCUMENTED BY THE PHARMACIST. The secondary objective, impact of CMR quality based on mode of delivery, will be assessed using chi-squared test. The secondary objective, SVI score and DTPs identified, will be evaluated using descriptive statistics and trend analysis. Study investigators will utilize the Centers for Disease Control and Prevention’s SVI from the U.S. Census Bureau of 2022 to determine community social vulnerability based on the PHARMACY’S geographic location. An internal retail data insight company will cross-reference SVI score with patient-specific information from the pharmacy management system and existing MTM platform to determine if a trend exists.

Results: N/A

Conclusions: N/A